a 5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L- methionine = a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-homocysteine
5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA
+
S-adenosyl-L- methionine
=
5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA
a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-triphosphoguanosine)- (2'-O-methyl-ribonucleoside) in mRNA + S-adenosyl-L-homocysteine + H+
5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA
+
S-adenosyl-L-methionine
=
5'-end (N(7)-methyl 5'-triphosphoguanosine)- (2'-O-methyl-ribonucleoside) in mRNA
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
Zika virus has emerged as a pathogen of major health concern. Here, we present a
high-resolution (1.62-Å) crystal structure of the RNA helicase from the French
Polynesia strain. The structure is similar to that of the RNA helicase from
Dengue virus, with variability in the conformations of loops typically involved
in binding ATP and RNA. We identify druggable 'hotspots' that are well suited
for in silico and/or fragment-based high-throughput drug discovery.